Dongsheng Cao

Dr. Dongsheng Cao

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Stem Cell Reviews and Reports
Verified
Journal Article
Open access
PDF file
DCDehui Che
Dehui Che
XXXinjian Xiang
Xinjian Xiang
JXJuan Xie
Juan Xie
ZCZenghong Chen
Zenghong Chen
QBQiong Bao
Qiong Bao
DCDongsheng Cao
Dongsheng Cao
Chronic trauma in diabetes is a leading cause of disability and mortality. Exosomes show promise in tissue regeneration. This study investigates the role of exosomes derived from adipose stem cells (ADSC-Exos) in angiogenesis. MiRNA-seq analysis revealed significant changes in 47 genes in human umbilical vein endothelial cells (HUVECs) treated with ADSC-Exos, with miR-146a-5p highly expressed. MiR-146a-5p mimics enhanced the pro-angiogenic effects of ADSC-Exos, while inhibitors had the opposite effect. JAZF1 was identified as a direct downstream target of miR-146a-5p through bioinformatics, qRT-PCR, and dual luciferase assay. Overexpress of JAZF1 resulted in decreased proliferation, migration, and angiogenic capacity of HUVECs, and reduced VEGFA expression. This study proposes that ADSC-Exos regulate angiogenesis partly via the miR-146a-5p/JAZF1 axis. Graphical Abstract

8 February 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
DCDehui Che
Dehui Che
ZJZhengwan Jiang
Zhengwan Jiang
XXXinjian Xiang
Xinjian Xiang
LZLingling Zhao
Lingling Zhao
XLXie Liu
Xie Liu
DCDongsheng Cao
Dongsheng Cao

30 November 2023 in Asian Journal of Surgery
Verified
Journal Article
Open access
XXXinjian Xiang
Xinjian Xiang
ZJZhengwan Jiang
Zhengwan Jiang
DCDehui Che
Dehui Che
GCGong Chen
Gong Chen
SSShichun Shen
Shichun Shen
DCDongsheng Cao
Dongsheng Cao
Progressive hemifacial atrophy (PHA) is a nonnegligible disease, and its treatment currently lacks consensus. We aim to conduct an analysis of PHA patients to summarize the postoperative effect. Moreover, we introduced the free serratus anterior muscle-fascial composite tissue flap as a safe and novelty surgical procedure for moderate-severe PHA. This clinical study included four patients who received a free serratus anterior muscle-fascial composite tissue flap and 19 patients who received Coleman fat transplantation. Preoperative (preoperative photograph and imageological examination) and postoperative (postoperative photograph, complications, therapeutic effect, and satisfaction) assessments were performed for all PHA patients. Body Image Concern Inventory (BICI), Self-rating Anxiety Scale (SAS), Self-rating Depression Scale (SDS) were performed preoperatively and postoperatively. All the cases were cured with a good appearance with two kinds of operations. Free serratus anterior muscle-fascial composite tissue flap could correct face defects in one surgery and achieve good long time and short-time postoperative satisfaction in moderate-severe PHA. Fat transplantation could also enhance appearance in numerous operations for mild-moderate PHA. The volume of free-fat grafts decreased obviously after implantation in many cases. So, many patients (42.11%) accepted a series of operations to achieve satisfied postoperative effect. BICI, SAS, SDS score decreased a year later in all patients. Free serratus anterior muscle-fascial composite tissue flap transplantation is an effective and safe treatment for moderate to severe PHA.

11 August 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Closed access
YCYujiao Cai
Yujiao Cai
YYYujie Ye
Yujie Ye
ZWZiyan Wang
Ziyan Wang
DCDehui Che
Dehui Che
BZBangzhong Zhu
Bangzhong Zhu
DCDongsheng Cao
Dongsheng Cao

8 November 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YHYe Huang
Ye Huang
MHMin Han
Min Han
YFYinglin Fu
Yinglin Fu
GWGuohang Wang
Guohang Wang
LKLiangliang Kong
Liangliang Kong
WLWeizu Li
Weizu Li

23 March 2026 in View
Verified
Journal Article
Open access
YCYujiao Cai
Yujiao Cai
JWJinnan Wang
Jinnan Wang
YLYan Liu
Yan Liu
XZXiaoke Zhu
Xiaoke Zhu
ZYZhanyuan Yuan
Zhanyuan Yuan
DCDongsheng Cao
Dongsheng Cao
Diabetic wounds are common and challenging complications of diabetes, characterized by delayed healing and an increased risk of infection. Exosomes derived from adipose‐derived stem cells (ADSCs) represent cell‐free therapeutic agents and are potential candidate drugs for treating diabetic wound healing. Our pre‐experimental and metabolomic analyses suggest that arachidonic acid (AA) metabolism can effectively promote wound healing in diabetic animal models. Exosomes from ADSCs pretreated with arachidonic acid (AA‐Exos) markedly improved the viability and proliferation of human umbilical vein endothelial cells under high glucose stress conditions, while also enhancing their biological functions, such as cell migration, angiogenesis, wound repair, and vascular endothelial growth factor (VEGF) expression. This study aimed to investigate the effect of AA‐Exos on the healing of diabetic wounds. Proteomic and transcriptomic analyses, along with pathway activation studies, revealed that AA‐Exos promoted angiogenesis by activating the PI3K/AKT/mTOR signaling pathway. In vivo experiments demonstrated that diabetic mice treated with AA‐Exos exhibited accelerated wound healing and increased vascularization. In addition, the compound stimulated collagen deposition and boosted VEGF and CD31 expression, indicating robust angiogenesis during diabetic wound healing. This study provides a novel perspective on exosome therapy for wound healing and effectively improves the therapeutic effects of exosomes.